| 李梦雅,周佳薇,仲子航,等.帕博利珠单抗治疗晚期胃腺癌、胃食管结合部腺癌患者的疗效与安全性—Keynote-061/062研究阴性结果解读[J].肿瘤学杂志,2022,28(7):614-623. |
| 帕博利珠单抗治疗晚期胃腺癌、胃食管结合部腺癌患者的疗效与安全性—Keynote-061/062研究阴性结果解读 |
| Efficacy and Safety of Pembrolizumab in Advanced Gastric Adenocarcinoma and Adenocarcinoma at the Gastroesophageal Junction： Interpretation of Negative Results in Keynote-061/062 Study |
| 投稿时间：2022-07-10 |
| DOI：10.11735/j.issn.1671-170X.2022.07.B016 |
|
 |
| 中文关键词: 帕博利珠单抗 胃腺癌 胃食管结合部腺癌 临床试验 阴性结果 |
| 英文关键词:pembrolizumab gastric adenocarcinoma gastroesophageal junction adenocarcinoma clinical trials negative result |
| 基金项目: |
|
| 摘要点击次数: 787 |
| 全文下载次数: 232 |
| 中文摘要: |
| 摘 要：探索帕博利珠单抗（Pembrolizumab）与紫杉醇比较在PD-L1阳性晚期胃/胃食管结合部腺癌临床疗效和安全性的两项全球多中心、随机对照、Ⅲ期研究（Keynote-061和062）均以失败告终，导致FDA撤销了Keytruda（可瑞达）在该适应证上的应用。两项研究样本量分别为592例和763例，主要终点均为总生存（overall survival，OS）。结果显示：帕博利珠单抗单药对比紫杉醇二线治疗 PD-L1联合阳性分数（combined positive score，CPS）≥1患者中两组中位总生存期分别为9.1个月和8.3个月，风险比（hazard ratio，HR）为0.82（95%CI：0.66~1.03，P=0.042 1），中位无进展生存期（progression-free survival，PFS）分别为1.5个月和4.1个月，风险比为1.27（95%CI：1.03~1.57）；一线治疗的患者（CPS1）帕博利珠单抗OS非劣效于化疗，HR为0.91（99.2%CI：0.69~1.18），PFS风险比为1.66（95%CI：1.37~2.01）；帕博利珠单抗联合化疗组相比化疗疗效改善没有明显优势，OS风险比为0.85（95%CI：0.70~1.03）；PFS风险比为0.84（95%CI：0.70~1.02）。但在安全性方面，帕博利珠单抗相对于化疗均表现出较好的安全性。帕博利珠单抗单药在晚期胃/胃食管结合部腺癌的研究结果为阴性，其研究策略、方案设计、统计分析、后续布局等均值得进一步讨论和思考。 |
| 英文摘要: |
| Abstract： Two global multicentral， randomized controlled， phase Ⅲ studies(Keynote 061 and Keynote 062) exploring the clinical efficacy and safety of pembrolizumab in PD-L1 positive advanced gastric/gastroesophageal junction adenocarcinoma patients ended in failure， leading the US Food and Drug Administration to withdraw Keytruda for this indication. The sample sizes of the two studies were 592 and 763 subjects， respectively， and the primary endpoint was overall survival(OS). The results showed that the median overall survival was 9.1 months and 8.3 months， respectively for pembrolizumab alone versus paclitaxel as second-line therapy(HR=0.82， 95%CI： 0.66~1.03； P=0.042 1） and median progression-free survival was 1.5 months for pembrolizumab and 4.1 months for paclitaxel(HR=1.27， 95%CI： 1.03~1.57) in CPS1 patients； the OS of pembrolizumab was non-inferior to chemotherapy as first-line treatment(CPS1)， with HR=0.91(99.2%CI： 0.69~1.18)， whereas， for PFS the HR was 1.66(95%CI： 1.37~2.01). Pembrolizumab in combination with chemotherapy had no significant improvement over chemotherapy(OS： HR=0.85， 95%CI： 0.70~1.03； PFS： HR=0.84， 95%CI： 0.70~1.02). But pembrolizumab showed better safety than chemotherapy. Although the research results of advanced gastric/gastroesophageal junction carcinoma is negative， its research strategy， protocol design， statistical analysis and subsequent layout are worthy of further discussion and consideration. |
|
在线阅读
查看全文 查看/发表评论 下载PDF阅读器 |